Cellectar Biosciences IncNASDAQ:CLRB
- LAST PRICE1.5700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.5600/ 8
- Ask / Lots1.5700/ 6
- Open / Previous Close1.5800 / 1.5700
- Day Range
- 52 Week Range
- Volume94,019
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLRB |
|---|---|---|
| 09:32 ET | 1895 | 1.6245 |
| 09:33 ET | 7275 | 1.6 |
| 09:35 ET | 10711 | 1.6 |
| 09:39 ET | 393 | 1.59 |
| 09:42 ET | 300 | 1.59 |
| 09:44 ET | 1000 | 1.58 |
| 09:46 ET | 100 | 1.575 |
| 09:48 ET | 2342 | 1.575 |
| 09:50 ET | 3300 | 1.5748 |
| 09:51 ET | 100 | 1.575 |
| 09:53 ET | 1670 | 1.59 |
| 09:55 ET | 9900 | 1.61 |
| 09:57 ET | 400 | 1.59 |
| 10:00 ET | 100 | 1.585 |
| 10:06 ET | 400 | 1.5899 |
| 10:08 ET | 425 | 1.585 |
| 10:11 ET | 1225 | 1.59 |
| 10:13 ET | 4500 | 1.57 |
| 10:18 ET | 764 | 1.5606 |
| 10:20 ET | 5902 | 1.55 |
| 10:22 ET | 100 | 1.55 |
| 10:26 ET | 2940 | 1.5438 |
| 10:29 ET | 165 | 1.545 |
| 10:33 ET | 540 | 1.555 |
| 10:38 ET | 12403 | 1.555 |
| 10:40 ET | 5100 | 1.56 |
| 10:42 ET | 200 | 1.555 |
| 10:45 ET | 3517 | 1.55 |
| 10:47 ET | 6668 | 1.55 |
| 10:51 ET | 500 | 1.55 |
| 10:54 ET | 100 | 1.555 |
| 10:56 ET | 159 | 1.5599 |
| 11:02 ET | 156 | 1.5579 |
| 11:03 ET | 100 | 1.56 |
| 11:05 ET | 900 | 1.56 |
| 11:07 ET | 603 | 1.56 |
| 11:09 ET | 1500 | 1.565 |
| 11:16 ET | 2100 | 1.57 |
Nov 19, 2024
DJ Cellectar Biosciences Is Maintained at Outperform by Oppenheimer, from 8:33AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:33AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 18, 2024
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update, from 7:05AM ET on Monday Nov 18, 2024 by Dow Jones
7:05AM ET on Monday Nov 18, 2024 by Dow Jones*DJ Cellectar Biosciences 3Q Loss/Shr 40c >CLRB, from 7:05AM ET on Monday Nov 18, 2024 by Dow Jones
7:05AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 14, 2024
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225, from 8:05AM ET on Thursday Nov 14, 2024 by Dow Jones
8:05AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer, from 8:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cellectar Biosciences Inc | 65.2M | -0.9x | --- |
DH Enchantment Inc | 59.8M | -70.0x | --- |
Hongchang International Co Ltd | 66.2M | -318.8x | --- |
Odonate Inc | 49.9M | -1,254.8x | --- |
Spectral Medical Inc | 107.2M | -6.1x | --- |
Global Pharmatech Inc | 67.2M | -1.8x | --- |
Company Information
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Contact Information
- Headquarters
- 100 Campus DriveFLORHAM PARK, NJ, United States 07932
- Phone
- 608-441-8120
- Fax
- 608-441-8121
Executives
- Independent Chairman of the Board
- Douglas Swirsky
- President, Chief Executive Officer, Director
- James Caruso
- Chief Financial Officer, Vice President, Secretary
- Chad Kolean
- Chief Operating Officer
- Jarrod Longcor
- Senior Vice President - Medical
- Andrei Shustov
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $65.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 41.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.91 |
EPS | $-1.67 |
Book Value | $-0.07 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
